Learning from combination HIV prevention programmes to face COVID-19 emerging pandemic
Main Article Content
Before a vaccine against SARS-CoV-2 became available, several measures to control COVID-19 pandemic are necessary. Analogously, in the absence of an available vaccine, Combination HIV Prevention Programmes have consolidated a large experience of biomedical, behavioral and structural interventions suitable for several epidemiological settings. Adaptation of such experiences can organize mid-term and long-term responses to face COVID-19
- COVID-19
- Coronavirus
- SARS Virus
- Condoms
- Acquired Immunodeficiency Syndrome
- Pandemics
- Asymptomatic Infections
- Personal Protective Equipment
- severe acute respiratory syndrome coronavirus 2
- Severe Acute Respiratory Syndrome
- Immunization
- VIH
Downloads
- Augusto Mathias, Lorruan Alves dos Santos, Alexandre Grangeiro, Marcia Thereza Couto, Thematic synthesis HIV prevention qualitative studies in men who have sex with men (MSM) , Colombia Medica: Vol. 50 No. 3 (2019)
- Ricardo Palacios, Forgotten, but not forgiven: facing immunization challenges in the 21st century , Colombia Medica: Vol. 49 No. 3 (2018)
- Ricardo Palacios, Considerations on immunization anxiety-related reactions in clusters , Colombia Medica: Vol. 45 No. 3 (2014)
- Ricardo Palacios, Post-trial access and the new version of the Declaration of Helsinki , Colombia Medica: Vol. 44 No. 4 (2013)
- Ricardo Palacios, El Documento de las Américas: Buenas Prácticas Clínicas para Autoridades Reguladoras , Colombia Medica: Vol. 40 No. 4 (2009)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use